HRTX Stock Price, Chart, Stats & News

Heron Therapeutics, Inc.
Save
64.76M
Market cap
–
Current P/E
46.95x
Forward P/E
HRTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 73.31% |
Operating margin | -1.64% |
Pretax margin | -13.04% |
Net margin | -13.04% |
Effective tax rate | – |
ROA | -7.89% |
ROE | 304.91% |
D/E | 9.81x |
Interest coverage ratio | -0.58x |
HRTX valuation
P/E | – |
P/S | 0.80x |
P/B | 9.12x |
P/CF | -4.74x |
P/FCF | -4.44x |
P/OCF | -4.74x |
PEG | 0.12x |
EV multiple | -0.97x |
About
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration.
Similar securities
Based on sector and market capitalization
Report issue











